Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related ENDP
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
US Stock Futures Up Ahead Of Economic Data
Related FHN
First Horizon Focused On Expansion; Time To Build Position?
First Tennessee Bank To Expand In North Carolina With Acquisition Of TrustAtlantic

Analysts at Cantor Fitzgerald downgraded Endo Health Solutions (NASDAQ: ENDP) from “hold” to “sell.” The target price for Endo Health Solutions is set to $30. Endo Health's shares closed at $35.96 yesterday.

Analysts at Morgan Stanley downgraded First Horizon National (NYSE: FHN) from “overweight” to “neutral.” The target price for First Horizon National is set to $11. First Horizon National's shares closed at $11.25 yesterday.

Analysts at Piper Jaffray downgraded Vera Bradley (NASDAQ: VRA) from “overweight” to “neutral.” The price target for Vera Bradley has been lowered from $32 to $24. Vera Bradley's shares closed at $22.46 yesterday.

Berenberg downgraded Oracle (NASDAQ: ORCL) from “buy” to “sell.” The target price for Oracle has been lowered from $35 to $28. Oracle's shares closed at $34.12 yesterday.

Latest Ratings for ENDP

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Oct 2014Cantor FitzgeraldUpgradesSellHold
Sep 2014RBC CapitalInitiates Coverage onOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ENDP + FHN)

Around the Web, We're Loving...

Get Benzinga's Newsletters